Trial · NCT02398201
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Respiratory Chain Enzyme Activity | baseline and 12 weeks | |
| Secondary | Change in citrate synthase | baseline and 12 weeks | |
| Secondary | Change in mitochondrial DNA copy number | baseline and 12 weeks | |
| Secondary | Change in COX negative fibres | baseline and 12 weeks | |
| Secondary | Change in serum Fibroblast Growth Factor-21 concentration | baseline, 3, 6, 9, 12 weeks | |
| Secondary | Change in PGC-1alpha concentration | baseline, 3, 6, 9, 12 weeks | |
| Secondary | Change in micro-RNA expression pattern | baseline, 3, 6, 9, 12 weeks | |
| Secondary | Change in cardiac 31P-MRS | baseline and 12 weeks | We will specifically analyse ATP production and muscle phosphocreatine pre and post bezafibrate |
| Secondary | Change in cardiac cine MRI | baseline and 12 weeks | We will analyse LV (left ventricular) torsion pre and post bezafibrate |
| Secondary | Change in skeletal muscle 31P-MRS | baseline and 12 weeks | We will analyse ATP production, muscle phosphocreatine, t1/2 PCR (phosphocreatine), muscle lipid content and volume. |
| Secondary | Change in IPAQ (international physical activity questionnaire) score | baseline, 6 and 12 weeks | |
| Secondary | Change in accelerometry | baseline, 6 and 12 weeks | |
| Secondary | Change in Timed Up and Go (TUG) time | baseline, 6 and 12 weeks | |
| Secondary | Change in NMDAS (Newcastle Mitochondrial Disease Adult Scale) score | baseline, 6 and 12 weeks | |
| Secondary | Change in heteroplasmy level | baseline and 12 weeks | measured in blood, urine and muscle |
| Secondary | Change in NMQ (Newcastle Mitochondrial Disease Quality of Life) Score | baseline, 6 and 12 weeks | |
| Secondary | Change in Fatigue Impact Scale score | baseline, 6 and 12 weeks | |
| Secondary | Number of Adverse Events | 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14 weeks | Adverse events will be captured every week with opportunistic capture between visits as required. |
| Secondary | Change in Full Blood Count | 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks | White cell count; Haemoglobin; Platelet count |
| Secondary | Change in Urea & Electrolytes | 0,1,2,3,4,5,6,7,8,9,10,11,12 weeks | Sodium; Potassium; Urea; Creatinine; |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02398201/registered